FibroBiologics has released and shipped the third batch of its CYWC628 drug product to Australia for a Phase 1/2 clinical trial targeting diabetic foot ulcers. The batch meets safety and quality standards under cGMP, supporting ongoing patient treatment. The company is optimistic about interim trial results expected in the second half of 2026, which could demonstrate the drug's effectiveness in accelerating wound healing. This progress is part of FibroBiologics' broader efforts to develop innovative therapies using fibroblast cells for chronic diseases.
Avalanche's AVAX price surged nearly 50% in a week, reaching an eight-month high of $10.82, driven by institutional interest and tokenization projects. Major catalysts include Intercontinental Exchange's ongoing testing of Avalanche for tokenized US ...
Lululemon's stock has dropped sharply from around $170 to under $100 per share, presenting what some investors see as a cheap valuation and buying opportunity. Despite operational challenges like a 12% sales drop in the Americas and an expected 10-11...
Most major cryptocurrencies, including Bitcoin, Ethereum, and Binance Coin, experienced price declines today, with Bitcoin down nearly 1% and Ethereum over 2%. However, some tokens like Avalanche (AVAX) and HBAR showed significant gains, rising 14.35...
AST SpaceMobile, Inc. is the subject of a securities fraud class action lawsuit filed for alleged false statements about its capital, liquidity, and competitive position between March 4, 2025, and July 15, 2026. The lawsuit claims the company oversta...
Liquidity pressures are building beneath the surface of the market, indicated by weakening breadth in both stocks and high-yield bonds despite stable headline indices. Key indicators like the NYSE Advance-Decline line and summation index show declini...
